Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for April 13, 2021

4/12/2021

 
Regulatory Update 
 
The FDA extended the review period for Pfizer’s abrocitinib by three months and moved the PDUFA date to the end of July.
 
The FDA granted eftilagimod alpha a Fast Track designation for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
 
Announced Research Updates
 
Fibrogen announced that safety data for roxadustat had inadvertently been miscalculated using post-hoc stratification factors. When the calculations were done using the pre-specified stratification factors approved by the FDA, the hazard ratios for MACE (all-cause mortality, stroke, and myocardial infarction), MACE+ (hospitalization due to heart failure and unstable angina added to MACE) and all-cause mortality were slightly higher for dialysis and non-dialysis patients.
 
The FDA requested additional information from Provention Bio regarding how the pharmacokinetic and pharmacodynamic (PK/PD) properties compare between templizumab manufactured by Lilly and AGC Biologics. Prevention Bio has used teplizumab manufactured by Lilly for its clinical trials. The company plans to have AGC Biologics manufacturer the drug for commercial use. The FDA did not find a PK/PD bridging study to support AGC Biologics manufactured templizumab to be comparable to the Lilly manufactured drug, so additional data would be required. While Prevention Bio believes this requirement will lead to a delay in approval of templizumab, there has not been a change in the PDUFA date or advisory committee meeting.
 
Published Research Updates 
 
ICER estimated the cost of treatment with ciltacabtagene autoleucel as $317,000 to be cost effective at $100,000 per quality adjusted life year (QALY) and $427,000 to be cost effective at $150,000 per QALY. ICER found the clinical evidence to support at least a small or substantial health benefit with a high likelihood of at least a net health benefit. 
 
The 748 patient, Phase III, MERU trial was terminated after an interim analysis did not find a survival benefit with rovalpituzumab as first-line maintenance therapy after platinum-based chemotherapy compared to placebo in patients with extensive-stage small cell lung cancer (SCLC) compared to placebo.
 
In the 26-week, 24 patient, Phase III, open-label CARDINAL trial, 13/24 (54.2%) patients treated with sutimlimab achieved an increase in hemoglobin of at least 2 g/dL or an average hemoglobin level of at least 12 g/dL and did not require a transfusion or pharmacotherapy between weeks 5 to 26 in patients with cold agglutinin disease.
 
In a 91 patient, Chinese, Phase II study anlotinib demonstrated an average progression free survival of 20.7 months compared to 11.1 months in patients with relapsed medullary thyroid carcinoma.
 
In the 6-week, 37 patient, Phase II, HELP trial, levosimendan did not reduce pulmonary capillary wedge pressure (PCWP) during exercise compared to placebo in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.